A Phase III, Open-label, Multicentre Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
The purpose of this study is to demonstrate superiority with regard to progression free
survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus
platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death
ligand 1+ (PD-L1+) tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society